Material agreementCompany-reported
What was reported
ALAMEDA, Calif., July 7, 2026 -- (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jul 7, 2026 · Open the source ↗
What the evidence supports
Vivani Medical told the SEC (Form 8-K, Item 1.01) that it signed an agreement it considers material, in this case connected to an acquisition or merger. The filing gives Jul 1, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
Whether the deal will close: completion usually depends on conditions and approvals. How the combined business will perform. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic WeightU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jul 7, 2026 · Open the source ↗
Press release lead paragraphALAMEDA, Calif., July 7, 2026 -- (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jul 7, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.